Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?
Xu
Jian-Ming
JM
Paradiso
Angelo
A
McLeod
Howard L
HL
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015195:Drug Design; D004341:Drug Evaluation; D066246:ErbB Receptors / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D066246:ErbB Receptors